International Journal of Cancer最新文献

{"title":"Should the age range of the Dutch hrHPV-based cervical cancer screening program be broadened? A modelling study using cohort effects.","authors":"Sylvia Kaljouw, Erik E L Jansen, Veerle J C Schevenhoven, Inge M C M de Kok","doi":"10.1002/ijc.35435","DOIUrl":"https://doi.org/10.1002/ijc.35435","url":null,"abstract":"<p><p>In the Netherlands, women are invited for human papillomavirus (HPV) screening between the ages of 30 and 60 (with conditional screening at age 65). However, an increase in cervical cancer (CC) incidence has been observed in younger women recently. Meanwhile, HPV-vaccinated cohorts reached the screening age of 30 in 2023. Moreover, increasing healthy life expectancy is a consideration for screening in older age groups. Due to these developments, the starting and ending ages of the HPV screening programs should be reconsidered. Microsimulation model MISCAN-Cervix was recalibrated for cohort effects using updated CC incidence data. We used this model to calculate the cost-effectiveness of screening unvaccinated women in birth cohorts 1962-1992 until 65 years old. Additionally, we considered starting screening at 25 for partly vaccinated cohorts (born in 2002-2006). Vaccination effects were calculated using microsimulation model STDSIM. Main outcome measures included cancers prevented, life years gained (LYG), costs, and referrals compared to the current strategy (2027 onwards). Adding screening at age 65 to the current strategy leads to +3.5% cancers prevented, +10.3% referrals, +2.4% LYG and +57.0% costs (cost-effectiveness ratio: €275,096/LYG). Adding screening at age 25 results in extra cases prevented (+1.3%-5.7%, depending on the target group's vaccination status) and LYG (+0.8%-3.7%), but increases referrals (12.9%-37.1%) and costs (+14.0%-33.1%) (cost-effectiveness ratio: €120,017-€323,813/LYG). So, screening unvaccinated women at 65 years old and screening women in (partly-)vaccinated cohorts at age 25 might not represent good value for money.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of circulating tumor DNA to detect minimal residual disease in colorectal cancer: A systematic review and network meta-analysis.","authors":"Tung Hoang, Moon Ki Choi, Jae Hwan Oh, Jeongseon Kim","doi":"10.1002/ijc.35442","DOIUrl":"https://doi.org/10.1002/ijc.35442","url":null,"abstract":"<p><p>Circulating tumor DNA (ctDNA) is a promising biomarker for predicting minimal residual disease (MRD) and guiding treatment decisions in patients with colorectal cancer (CRC). This study aimed to examine the study designs and settings of ongoing clinical trials that use ctDNA to guide treatment decisions and to determine the best timing for detecting MRD in non-metastatic CRC. We searched PubMed, Embase, Web of Science, Cochrane Library, and clinicaltrials.gov for English language records. The ctDNA settings from the clinical trials were categorized by randomization to ctDNA testing, treatment options based on ctDNA results, and the timing of ctDNA testing relative to adjuvant therapy. For prospective studies, a network meta-analysis using a frequentist approach was conducted to examine the pairwise associations between different ctDNA timing strategies and MRD, defined as recurrence, relapse, and progression. The main approaches in ctDNA-based interventional trial designs were categorized as ctDNA-guided treatment, ctDNA-by-treatment, ctDNA-guided surveillance, and ctDNA-enriched adjuvant therapy for guiding treatment decisions, including both escalation and de-escalation strategies, and surveillance. Overall, both preoperative and postoperative ctDNA detection were linked to higher risks of progression, with pooled hazard ratios (95% confidence intervals) of 5.23 (2.10-13.00) and 7.95 (5.30-11.91), respectively. Among the timing strategies, ctDNA testing after adjuvant therapy was the most effective for identifying high-risk patients, strongly suggesting the presence of residual disease. This study comprehensively reviewed the clinical settings of ctDNA testing in ongoing trials and provided evidence supporting the selection of post-adjuvant therapy as the optimal timing for ctDNA testing.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-derived tumor organoids highlight the potential of precision medicine in managing pancreatic ductal adenocarcinoma.","authors":"Christine Nitschke, Charline Phan, Yara Souto, Philipp Walter, Mara Goetz, Gediminas Simkus, Jacob Thastrup, Ronald Simon, Jürgen Kupper, Jakob Izbicki, Steven A Johnsen, Thilo Hackert, Marianne Sinn, Harriet Wikman, Faik G Uzunoglu, Tabea M Sturmheit","doi":"10.1002/ijc.35443","DOIUrl":"https://doi.org/10.1002/ijc.35443","url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma (PDAC) ranks among the most lethal cancers, with only 20% of patients qualifying for curative treatment at diagnosis. Three-dimensional tumor organoids capturing patient-specific features of PDAC serve as a valuable disease model. We employed this technology to assess drug sensitivities of patient-derived tumor organoids to clinically relevant drugs and combinations, evaluated culture success rates, and correlated in vitro data with clinicopathological and follow-up information. Tumor organoid cultures were established from PDAC patients undergoing surgical resection (or liver biopsy) and follow-up at a single medical center. Patient-derived cultures displaying sustained growth were analyzed regarding their molecular subtype and utilized for functional drug sensitivity testing (f-DST). Correlative analyses of our PDAC patient cohort (n = 67; n = 42 patients with curative tumor resection and n = 25 palliative patients) revealed a link between tumor organoid growth and reduced patient survival. Furthermore, drug sensitivity profiles (obtained of 10 patient-derived cultures) revealed notable inter-individual differences and mirrored clinical responses to administered drug therapies. f-DST was applicable across tumor organoid cultures of both classical and basal subtype, according to the Purity Independent Subtyping of Tumors (PurIST) classifier. This pilot study confirms the feasibility of deriving and maintaining tumor organoid cultures from heterogeneous samples. Cultures displaying sustained proliferation correlated positively with advanced-stage tumors (Tumour, Node, Metastasis (UICC) stages III and IV). Individual patient case analyses integrating in vitro drug sensitivity profiles with clinical follow-up data suggest that f-DST using tumor organoids could guide future therapeutic strategies. In summary, tumor organoids offer insights into patient-specific responses to treatment, highlighting the potential of precision medicine in managing this challenging cancer.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GREM1 deficiency induced bone marrow adipose niche promotes B-cell acute lymphoblastic leukemia disease progression.","authors":"Lili Song, Rui Zhang, Liya Pan, Qiang Mi, Yi Yang, Xiang Wang, Yani Ma, Shuhong Shen, Benshang Li, Yanxin Li, Li Hong","doi":"10.1002/ijc.35418","DOIUrl":"https://doi.org/10.1002/ijc.35418","url":null,"abstract":"<p><p>Relapse and disease progression are the primary causes of treatment failure and subsequent mortality in children with B-cell acute lymphocytic leukemia (B-ALL). At diagnosis and during treatment, dyslipidemia and the bone marrow adipose microenvironment are commonly observed in pediatric leukemia. However, the intricate connection between these factors and disease progression remains largely unexplored. We found that abnormal triglyceride accumulation increased the risk of death. Further investigation into the adipogenic potential of BM-MSCs revealed a correlation between higher adipogenicity and elevated serum TG levels, which subsequently led to the rapid proliferation of leukemia cells and heightened the risk of post-relapse mortality. Through RNA sequencing, Gremlin1 (GREM1) was identified as an important factor affecting adipogenicity. Silencing of GREM1 in BM-MSCs induced adipogenic differentiation, partly through the BMP/SMAD signaling pathway. In an in vitro co-culture model, shGREM1-MSCs promoted B-ALL cell proliferation and induced drug resistance to dexamethasone, while increasing sensitivity to L-asparaginase. Furthermore, GREM1-deficient BM-MSCs promoted B-ALL disease progression in xenograft models. This study provides new insights into overcoming drug resistance, relapse, and death by elucidating the novel mechanism by which GREM1 deficiency induces adipogenic differentiation of BM-MSCs and promotes B-ALL disease progression.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A heterodimer of hemoglobin identifies theranostic targets on brain-metastasizing melanoma cells.","authors":"Maharrish Chelladurai, Orit Sagi-Assif, Shlomit Ben-Menachem, Tsipi Meshel, Metsada Pasmanik-Chor, Sivan Izraely, Dave S B Hoon, Isaac P Witz","doi":"10.1002/ijc.35458","DOIUrl":"https://doi.org/10.1002/ijc.35458","url":null,"abstract":"<p><p>Cancer microenvironments encompass both cancer-promoting and cancer-restraining factors. If these factors cancel each other, cancer dormancy may ensue. In search of microenvironmental factors that keep dormant lung-metastasizing neuroblastoma cells and brain-metastasizing melanoma cells (BMMC) in check, we identified the beta subunit of hemoglobin and a heterodimer of alpha and beta chains of hemoglobin (α/β dimer) in the lung and brain microenvironments, respectively, as anti-metastatic factors. A previous study demonstrated that the α/β dimer triggers programmed cell death of BMMC and downregulates the expression of BRD4, GAB2, and IRS2 proteins, which perform essential functions in tumorigenesis and progression. The working hypothesis of the present study is that in addition to its tumoricidal function, the α/β dimer serves as a pathfinder for the identification of therapy targets for BMMC. We, therefore, employed small-molecule inhibitors of Bromodomain-containing protein 4 (BRD4), GRB2-associated-binding protein 2 (GAB2), and Insulin receptor substrate 2 (IRS2) as potential anti-BMMC agents. A combination of sub-lethal concentrations of BRD4 and IRS2 inhibitors synergistically arrested BMMC at the subG1 phase of the cell cycle and killed more than 70% of BMMCs. The BRD4/IRS2 inhibitor cocktail (designated hereafter as BRIRi) moderated the malignancy of BMMC lines from four different human melanomas. Preliminary results suggest that the BRIRi modulated \"cold\" BMMC to \"hot\" ones. Among the top enriched functions of differentially expressed genes identified by RNAseq of BRIRi-treated versus control BMMC, TNF and apoptotic signaling pathways were observed. We propose that co-targeting BRD4 and IRS2 offers a promising approach for treating BMMC.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From non-coding RNAs to cancer regulators: The fascinating world of micropeptides.","authors":"Can Li, Dan Zhang, Jinxi Huang, He Zhou, Tao Song, Xianyao Wang, Qinghong Kong, Liujin Li, Zhaohui Liu, Neng Zhang, Yanxin Lu, Jun Tan, Jidong Zhang","doi":"10.1002/ijc.35459","DOIUrl":"https://doi.org/10.1002/ijc.35459","url":null,"abstract":"<p><p>Micropeptides are commonly identified as peptides encoded by non-coding RNAs (ncRNAs). In the short open reading frame (sORF) of ncRNAs, there is a base sequence encoding functional micropeptides, which is of great significance in the biological field. Recently, micropeptides regulate diverse processes, including mitochondrial metabolism, calcium transport, mRNA splicing, signal transduction, myocyte fusion, and cellular senescence, regulating the homeostasis of the internal environment and cancer's incidence and progression. Especially, the study of micropeptides in cancer about the potential regulatory mechanism will be conducive to further understanding of the process of cancer initiation and development. More and more research shows micropeptides have been confirmed to play an essential role in the emergence of multiple kinds of cancers, including Breast cancer, Colon cancer, Colorectal cancer, Glioma, Glioblastoma, and Liver cancer. This review presents a comprehensive synthesis of the latest advancements in our understanding of the biological roles of micropeptides in cancer cells, with a particular focus on the regulatory networks involving micropeptides in oncogenesis. The new mode of action of micropeptides provides innovative ideas for cancer diagnosis and treatment. Moreover, we explored the significant capacity of micropeptides as diagnostic biomarkers and targets for anti-cancer therapies in cancer clinical settings, highlighting their role in the development of innovative micropeptide-based diagnostic tools and anti-cancer therapeutics.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD?","authors":"Christoph Schubart, Lars Tögel, Maria Giulia Carta, Philip Hetzner, Lina Helbig, Charlotte Zaglas, Maria Ziegler, Robert Stöhr, Annett Hölsken, Juliane Hoyer, Fulvia Ferrazzi, Clemens Neufert, Sebastian Lettmaier, Marianne Pavel, Henriette Golcher, Sarina K Mueller, Florian Fuchs, Carla E Schulmeyer, Matthias W Beckmann, Bernd Wullich, Abbas Agaimy, Andre Reis, Arndt Hartmann, Norbert Meidenbauer, Silvia Spoerl, Florian Haller, Evgeny A Moskalev","doi":"10.1002/ijc.35457","DOIUrl":"https://doi.org/10.1002/ijc.35457","url":null,"abstract":"<p><p>Alterations in Homologous Recombination Repair (HRR) Pathway genes have been found to be associated with HR-Deficiency (HRD), which is an approved biomarker for PARP Inhibitor (PARPi) treatment. The aim of a Molecular Tumor Board (MTB) is to identify molecular alterations in cancer patients with advanced tumors that may suggest off-label treatment options. So far, few studies have analyzed the presence of HRR gene mutations and their association with HRD outside of clinical studies. Currently, no data on HRD testing in the setting of a MTB have been published. For the present study, a cohort of 237 patients encompassing 24 different tumor entities was collected from the MTB of the Comprehensive Cancer Center Erlangen-EMN. We show that an elevated Genomic Instability Score (GIS ≥42) can occur in samples with and without mutations in HRR-related genes. Overall, 38.1% of cancer samples with BRCA1/2 mutations, 10.9% of tumors with alterations in HRR genes other than BRCA1/2, and 4.3% of cancer samples without HRR gene mutations harbored an elevated GIS. Notably, our data show that various inactivating BRCA1/2 mutations are not associated with an elevated GIS. Taken together, panCancer assessment of HRD in addition to BRCA1/2 and other HRR gene mutational analysis is recommended to guide decisions regarding PARPi treatment. Further studies are needed to establish thresholds for GIS in non-ovarian cancer entities. Finally, HRD can be observed in 4.3% of BRCA1/2 and other HRR gene wildtype cancer samples, and may emerge as an independent biomarker for PARPi in the future.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world comparative effectiveness and safety of Pertuzumab in patients with HER2+ metastatic breast cancer: A pan-Canadian population-based cohort study.","authors":"Caroline E Muñoz, Wei Fang Dai, Winson Y Cheung, Claire de Oliveira, Reka E Pataky, Philip Q Ding, David A Tran, Zeb Aurangzeb, Chenthila Nagamuthu, Ning Liu, Lynn Lethbridge, Carol McClure, Kim Vriends, Hui Xiong, Chris Folkins, Chandy Somayaji, Stuart Peacock, Riaz Alvi, Donna Turner, Carrie O'Conaill, Ted McDonald, Robin Urquhart, Cynthia Kendell, Jeff Dowden, Erin Strumpf, Avram Denburg, Jaclyn M Beca, Rebecca E Mercer, Mina Tadrous, Pam Takhar, Kelvin K W Chan","doi":"10.1002/ijc.35448","DOIUrl":"https://doi.org/10.1002/ijc.35448","url":null,"abstract":"<p><p>We assessed the comparative effectiveness and safety of pertuzumab plus trastuzumab and chemotherapy versus trastuzumab and chemotherapy for patients with HER2+ metastatic breast cancer (mBC) in Canada. We conducted a population-based retrospective study of patients receiving first-line treatment for mBC across eight Canadian provinces. Patients receiving trastuzumab and chemotherapy were historical comparators, and patients receiving pertuzumab plus trastuzumab and chemotherapy were the treatment group. Patients were followed until death or up to 5 years following the start of treatment (maximum follow-up to December 31, 2019). The primary outcome was overall survival (OS). One-year cumulative incidence and RDs were calculated for safety outcomes including hospitalization, emergency department visits, febrile neutropenia, and cardiac-related events. Propensity score matching (PSM) and inverse-probability of treatment weighting (IPTW) were applied within provinces. Individual provincial survival estimates were pooled using random effects meta-analysis. 3063 patients who received first-line treatment for mBC were identified. Median OS was higher among treatment patients compared to comparator patients in most provinces. Pertuzumab was associated with a statistically significantly lower risk of mortality (pooled HRs, PSM: 0.65, 95%CI: 0.57-0.74; IPTW: 0.65, 95% CI: 0.61-0.70). The treatment group had a lower risk of hospitalization compared to the comparator group (pooled RD: -0.05, 95% CI: [-0.09]-[-0.01]). No difference in 1-year cumulative incidence of cardiac-related events was identified between groups. Pertuzumab use in practice was associated with statistically significant improved survival without apparent safety concerns among patients with mBC. Real-world evaluations allow for assessments of publicly funded treatments to inform funding policies.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neck management in cT1-2N0 oral squamous cell carcinoma: Act or watchful wait?","authors":"Zi-Zhan Li, Li-Ya Wei, Lei-Ming Cao, Guang-Rui Wang, Kan Zhou, Yao Xiao, Han-Yue Luo, Si-Jie Zhang, Qiuji Wu, Bing Liu, Lin-Lin Bu","doi":"10.1002/ijc.35455","DOIUrl":"https://doi.org/10.1002/ijc.35455","url":null,"abstract":"<p><p>The controversy over neck management for cT1-2N0 OSCC patients has persisted for two decades. While selective neck dissection (SND) has been deemed effective, only 30% of patients actually exhibit lymph node metastasis (LNM). SND-related complications, such as shoulder dysfunction and lymphedema, significantly impact patient quality of life, suggesting that 70% of patients may not benefit from SND. Current guidelines advocate observation, sentinel lymph node biopsy (SLNB), and SND, but the appropriate scenarios for each strategy need further exploration. Risk stratification assessment can inform treatment decisions in early-stage OSCC. This review explores histological risk factors, SLNB, gene expression profiles, and biomarkers for risk stratification. Additionally, we assess the potential value of postoperative radiotherapy (PORT) and immunotherapy, particularly immune checkpoint blockade (ICB), in cT1-2N0 OSCC. Risk-stratified approaches align with personalized medicine and precision surgery trends, while PORT and ICB may offer more reliable neck management options. This comprehensive review systematically synthesizes the past selection of therapeutic strategies for cT1-2N0 OSCC patients, alongside their respective strengths and limitations. We aspire to contribute to the optimization of treatment strategies for early-stage OSCC patients, ultimately enhancing both survival outcomes and quality of life.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of ALA-PDT in treating cervical low-grade squamous intraepithelial lesions with high-risk HPV patients: A multicentre randomized controlled trial.","authors":"Yingting Wei, Liying Gu, Youzhong Zhang, Qiuyun Yang, Fei Chen, Zubei Hong, Wen Di, Lihua Qiu","doi":"10.1002/ijc.35450","DOIUrl":"https://doi.org/10.1002/ijc.35450","url":null,"abstract":"<p><p>Persistent infection with high-risk human papillomavirus (hrHPV) is a major cause of cervical cancer. Current management of low-grade squamous intraepithelial lesions (LSIL) primarily involves monitoring, though some cases progress to cervical precancer or cancer, requiring timely intervention. This study aimed to evaluate the efficacy of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in treating cervical LSIL with hrHPV infection. A total of 155 women with LSIL and hrHPV infection were enrolled and randomly assigned to either the treatment group, which received six sessions of ALA-PDT, or the control group, which underwent routine follow-up. Outcomes were assessed at 6 and 12 months using hrHPV testing, cytology, colposcopy, and biopsy. Results showed that ALA-PDT significantly improved lesion regression and hrHPV clearance rates at both 6 and 12 months. At 6 months, the lesion regression rate in the treatment group was 80.43% versus 56.10% in the control group (p = 0.0203), and the hrHPV clearance rate was 61.96% versus 29.27% (p = 0.0005). At 12 months, both rates remained significantly higher in the treatment group. Age was found to influence hrHPV clearance, with younger women (<45 years) showing significantly higher clearance rates. ALA-PDT was well tolerated, with only minor side effects, such as localized pain and pruritus, reported. The study suggests that ALA-PDT is a safe, effective, and non-invasive treatment option for patients with cervical LSIL and hrHPV infection who require active intervention.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}